Chronic Idiopathic Constipation Drugs Market 2016 Segmentation, Demand, Growth, Trend, Opportunity and Forecast to 2022
The latest market report published by Credence Research, Inc. “Global Chronic Idiopathic Constipation (CIC) Drugs Market - Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2016-2022,” the chronic idiopathic constipation (CIC) drugs market was valued at USD 1675.4 Mn in 2015, and is expected to reach USD 2570.8 Mn by 2022, expanding at a CAGR of 6.4% from 2016 to 2022; where Europe has the largest market share.
Browse the full report Chronic Idiopathic Constipation (CIC) Drugs Market - Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2016–2022 at http://www.credenceresearch.com/report/chronic-idiopathic-constipation-cic-drugs-market
Market Insights
Chronic idiopathic constipation (CIC) is a common gastrointestinal disorder. The currently available treatment options, both prescription based and OTC have demonstrated limited efficacy in a considerable set of patients. Thus there is a major demand for more effective medications for the treatment of CIC. Linaclotide is a secretagogue and has novel action mechanism; it has low oral bioavailability and has demonstrated the least systemic side effects. Through several clinical trials, Linaclotide has demonstrated greater efficacy in treating both CIC and irritable bowel syndrome induced constipation.
Currently North America is the largest regional market for CIC drugs at a market share of approximately 50%. It is also expected that the region will progress at the fastest CAGR of above 8% during the forecast period. Higher awareness among physicians and patient population significantly contribute the market growth in the region. Earliest commercialization of the drug in the US also adds up to the high demand of the drug in North America market. On the other hand, gradual introduction of Linaclotide in other developing markets will facilitate market growth in Asia Pacific market. China, Japan, Australia and India are the major national markets that are expected to give highest revenue contributions to the Asia Pacific CIC drugs market. Also, supporting the established fact of correlation between age and risk of CIC, it is reported that China and Japan will be the largest national markets for CIC drugs in Asia Pacific.
Overall, the CIC drugs market is open for further innovations, anticipating introduction of novel therapeutic options in the global market. Intensive research and development activities undertaken by the major market players indicate further competition in the market in the next ten years.
Table of Content
Chapter 1 Preface
1.1 Report Scope and Description
1.2 Research Methodology
Chapter 2 Executive Summary
Chapter 3 Global CIC Drugs Market Analysis
3.1 CIC Drugs Market Overview
3.2 Market Inclination Insights
3.3 Attractive Investment Proposition, 2015
3.4 Market Dynamics
3.4.1 Drivers
3.4.1.1 Adverse health effects from modern dietary habits
3.4.1.2 Cancer or other systematic disease
3.4.1.3 Increasing geriatric population
3.4.1.4 Better and effective drugs in pipeline
3.4.1.5 Increasing constipation problems as a side-effect frequently prescribed medicines
3.4.2 Restraints
3.4.2.1 Surgical treatments
3.4.2.2 Unawareness and Ignorance among people
3.4.2.3 Side-effects of the chronic idiopathic constipation drugs
3.4.3 Opportunities
3.4.3.1 Emerging APAC market
3.4.3.2 High unmet needs
3.5 Attractive Investment Proposition, 2015
3.6 Market Positioning of Key CIC Drugs Manufacturers
Chapter 7 Company Profiles
7.1 Actavis
7.1.1 Overview
7.1.2 Actavis Product Portfolio
7.1.3 Strategic Moves
7.1.4 SCOT Analysis
7.2 Chugai Pharmaceutical
7.2.1 Overview
7.2.2 Chugai Pharmaceuticals Products Portfolio
7.2.3 Strategic Moves
7.2.4 SCOT Analysis
7.3 Ferring International Center S.A.
7.3.1 Overview
7.3.2 Ferring Holdings Products Portfolio
7.3.3 SCOT Analysis
7.4 Synergy Pharmaceuticals
7.4.1 Overview
7.4.2 Synergy Pharmaceuticals Products Portfolio
7.4.3 SCOT Analysis
7.5 Pfizer
7.5.1 Overview
7.5.2 Pfizer Product Portfolio
7.5.3 SCOT Analysis
7.6 GlaxoSmithKline
7.6.1 Overview
7.6.2 GlaxoSmithKline Product Portfolio
7.6.3 SCOT Analysis
7.7 Roche Holding AG
7.7.1 Overview
7.7.2 Roche AG Product Portfolio
7.7.3 Strategic Moves
7.7.4 SCOT Analysis
7.8 Sanofi
7.8.1 Overview
7.8.2 Sanofi Products Portfolio
7.8.3 SCOT Analysis
7.9 Bayer AG
7.9.1 Overview
7.9.2 Bayer AG Products Portfolio
7.9.3 SCOT Analysis
7.10 Salix Pharmaceuticals Ltd
7.10.1 Overview
7.10.2 Salix Pharmaceuticals Product Portfolio
7.10.3 SCOT Analysis
7.11 Sucampo Pharmaceuticals Inc
7.11.1 Overview
7.11.2 Sucampo Pharmaceuticals Product Portfolio
7.11.3 SCOT Analysis
7.12 Ironwood Pharmaceuticals inc
7.12.1 Overview
7.12.2 Ironwood Pharmaceuticals Product Portfolio
7.12.3 SCOT Analysis
7.13 Progenics pharmaceuticals inc
7.13.1 Overview
7.13.2 Progenics Pharmaceuticals product portfolio
7.13.3 SCOT Analysis
Download Free Sample: http://www.credenceresearch.com/sample-request/57738
Latest Reports:
Our Blogs: http://www.mobilecomputingtoday.co.uk/6340/chronic-idiopathic-constipation-cic-drugs-market-expanding-cagr-6-43-2017-2025-credence-research/
http://www.technicaltop.com/2018/05/11/chronic-idiopathic-constipation-cic-drugs-market-size-share-growth-analysis-and-forecast-2016-2022/
About Us
Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non-legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we've manufactured a firm extraordinarily prepared to this task.
Who we are
Credence Research is a worldwide firm, containing more than 15 research consultants and almost 100 research and information professionals.
Our customers mirror our worldwide nature. Around 45% are in Europe, 30% in the Americas, 13% in Asia Pacific and 12% in the Middle East and Africa.
Our firm is intended to work as one. We are a solitary global research organization united by a solid arrangement of qualities, concentrated on customer effect.
Media Contact
Name: Chris Smith
Address: 105 N 1st ST #429,
SAN JOSE, CA 95103 US
E-mail: [email protected]
Ph.: 1-800-361-8290
Website: http://www.credenceresearch.com